| Serial Number | 97096948 |
| Word Mark | PREDICTGEN |
| Filing Date | Thursday, October 28, 2021 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Friday, May 10, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, September 19, 2023 |
| Pseudo Mark | PREDICT GEN |
| Goods and Services | Scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of blood samples for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of blood samples for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, the monitoring and diagnostics of patient drug compliance, data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching, all for research purposes and not for medical purposes; scientific and technological services in the field of pharmaceuticals featuring pharmacogenomic testing analysis and evaluation of buccal, saliva and other biological samples for the purposes of analyzing how an individual's genetic and non-genetic factors affect their response to drugs, improving drug selection and dosage recommendations, selecting initial and subsequent medications, identifying drug-drug interactions, avoiding adverse drug reactions, developing clinical treatment decision support recommendations, and supporting other medical diagnostic products and prescription drugs; scientific and technological services in the field of pharmaceuticals, namely, scientific testing, research, and analysis for the purpose of determining a patient's disease and drug response phenotype through evaluation of chromatin state, genomic regulatory elements, epigenomics, proteomics, metabolomics, transcriptomics, environmental factors, sociological factors, age, biological sex, ethnicity, and other non-genetic factors to predict pharmacological drug efficacy and adverse drug reaction phenotypes for patients; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of buccal, saliva, blood and other biological samples for the purposes of supporting drug clinical trials and research into the field of new drug development and drug repurposing |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, November 9, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Phenomics Health Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Plymouth, MI 48170 |
| Party Name | Phenomics Health Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Plymouth, MI 48170 |
| Event Date | Event Description |
| Monday, November 1, 2021 | NEW APPLICATION ENTERED |
| Tuesday, November 9, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, July 5, 2022 | NON-FINAL ACTION WRITTEN |
| Wednesday, June 15, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, July 5, 2022 | NON-FINAL ACTION E-MAILED |
| Tuesday, July 5, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, January 3, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, January 3, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 3, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, February 1, 2023 | FINAL REFUSAL WRITTEN |
| Wednesday, February 1, 2023 | FINAL REFUSAL E-MAILED |
| Wednesday, February 1, 2023 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Thursday, April 27, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Thursday, April 27, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Monday, July 31, 2023 | EXPARTE APPEAL RECEIVED AT TTAB |
| Monday, July 31, 2023 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Monday, July 31, 2023 | EX PARTE APPEAL-INSTITUTED |
| Monday, July 31, 2023 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Wednesday, August 16, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, August 16, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, August 16, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, September 19, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, August 30, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, September 19, 2023 | PUBLISHED FOR OPPOSITION |
| Friday, May 10, 2024 | SOU TEAS EXTENSION RECEIVED |
| Friday, May 10, 2024 | SOU EXTENSION 1 GRANTED |
| Friday, May 10, 2024 | SOU EXTENSION 1 FILED |
| Saturday, May 11, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, November 14, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |